Intercept's NASH decision delayed by FDA, but don't panic: analysts

Intercept Pharmaceuticals has been gearing up for the potential launch of its nonalcoholic steatohepatitis (NASH) med, but now its wait looks a little longer.

While the FDA was originally due to decide on the company’s application for obeticholic acid by March 26, 2020, Intercept said Friday that date wouldn't work. That’s because the agency has set an advisory committee hearing to review the application April 22.